Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H14N2O2S |
| Molecular Weight | 226.295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](S)[C@@H](CC1=CN=C(N)C=C1)C(O)=O
InChI
InChIKey=GYIYAOUGKJSCCG-HTRCEHHLSA-N
InChI=1S/C10H14N2O2S/c1-6(15)8(10(13)14)4-7-2-3-9(11)12-5-7/h2-3,5-6,8,15H,4H2,1H3,(H2,11,12)(H,13,14)/t6-,8-/m1/s1
| Molecular Formula | C10H14N2O2S |
| Molecular Weight | 226.295 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. | 2001 Aug |
|
| The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. | 2001 Aug |
|
| Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. | 2001 Jan |
|
| The possible neuroprotective effect of laudanosine, an atracurium and cisatracurium metabolite. | 2003 Jul |
|
| Instability of pancuronium in postmortem blood and liver taken after a fatal intramuscular Pavulon injection. | 2004 Jul 16 |
|
| Perinatal neuroprotection by muscle relaxants against hypoxic-ischemic lesions: is it a possible hypothesis? | 2005 Aug |
|
| Anesthesiologist suicide with atracurium. | 2006 Mar |
|
| Determination of atracurium, cisatracurium and mivacurium with their impurities in pharmaceutical preparations by liquid chromatography with charged aerosol detection. | 2010 Feb 19 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:12:50 GMT 2023
by
admin
on
Sat Dec 16 12:12:50 GMT 2023
|
| Record UNII |
84KQ4M4N8B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
87609775
Created by
admin on Sat Dec 16 12:12:50 GMT 2023 , Edited by admin on Sat Dec 16 12:12:50 GMT 2023
|
PRIMARY | |||
|
DB05712
Created by
admin on Sat Dec 16 12:12:50 GMT 2023 , Edited by admin on Sat Dec 16 12:12:50 GMT 2023
|
PRIMARY | |||
|
84KQ4M4N8B
Created by
admin on Sat Dec 16 12:12:50 GMT 2023 , Edited by admin on Sat Dec 16 12:12:50 GMT 2023
|
PRIMARY | |||
|
775274-06-1
Created by
admin on Sat Dec 16 12:12:50 GMT 2023 , Edited by admin on Sat Dec 16 12:12:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
2.3.9 AZD-9684 (carboxypeptidase U inhib-Astr, CPU inhibitor-AstraZeneca) AZD-9684 (carboxypeptidase U inhib-Astr, CPU inhibitor-
AstraZeneca; AstraZeneca), a carboxypeptidase U (CPU)
inhibitor, was under development for the treatment of thrombosis. AZD-9684 inhibits CPU, which removes C-terminal lysines from partially degraded thrombin and impairs plasminogen activation and subsequent fibrinolysis. Phase II development was underway however,development has been discontinued.
|
||
|
ACTIVE MOIETY |
Fifty-eight patients with confirmed PE were randomized to receive AZD9684 or placebo, on top of once-daily dalteparin for 57 days. In the patient group receiving AZD9684, fibrinolysis biomarkers in plasma were higher and sustained for a longer period of time, implying that inhibition of CPU by AZD9684 stimulates endogenous fibrinolysis. Moreover, lung deficiency scintigraphy scores improved over the treatment period. In addition, no difference in the occurrence of adverse effects was seen between both treatment groups.
|
